DDInter93 DDInter596
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Anagrelide may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Anagrelide (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Doxorubicin (Compound)
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Doxorubicin (Compound)
Anagrelide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Doxorubicin (Compound)
Anagrelide (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Doxorubicin (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)